Effect of Dienogest therapy on the size of the endometrioma

Michele Vignali, M. Vignali, Gaia Maria Belloni, Giuliana Pietropaolo, Allegra Barbasetti di Prun, Valeria Barbera, Stefano Angioni, Ida Pino
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2020 · vol. 36(8) , pp. 723–727 · doi:10.1080/09513590.2020.1725965 · PMID:32065005 · W3006613875
article OA: closed CC0 ⤵ 33 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Dienogest 2 mg daily significantly reduced endometrioma volume by 66.71% after 6 months and 76.19% after 12 months, along with substantial pain symptom relief.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Studies have been published on the efficacy of Dienogest in the management of pain symptoms in endometriosis. Nonetheless, few data are available on the reducing effect on endometrioma’s size. The aim of the study was to evaluate if Dienogest could determine significant changes in size, as well as in symptoms. In this prospective observational study, patients were enrolled with pain symptoms and at least one endometrioma diagnosed via TV-US. The volume of the endometrioma and pain symptoms was measured according to the LxDxWx0.5233 formula and VAS, respectively. Dienogest 2 mg was administered daily. Follow-up visits were scheduled after 6 and 12 months of treatment to assess changes in patients' symptoms and endometrioma’s volume. Seventy patients were enrolled, 63 patients completed a 6-month treatment. The reduction of the mean volume after 6 months was 66.71%. Fifty-eight patients completed the 12 month-treatment. The reduction of the mean volume after 12 months was 76.19%. Dysmenorrhea showed a 74.05% reduction after 6 months and a 96.55% reduction after 12 months. Patients reported a reduction in dyspareunia and chronic pelvic pain of 42.71% and 48.91% after 6 months and 51.93% and 59.96% after 12 months, respectively. Dienogest leads to a statistically significant reduction of endometrioma’s volume and pain symptoms.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

dysmenorrheadyspareuniaendometriosischronic_pelvic_painendometrioma

MeSH descriptors

Endometriosis Endometriosis Nandrolone Peritoneal Diseases Peritoneal Diseases Adult Dysmenorrhea Dysmenorrhea Dysmenorrhea Dysmenorrhea Dyspareunia Dyspareunia Dyspareunia Dyspareunia Endometriosis Endometriosis Endometrium Endometrium Endometrium Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (46)

Cited by (33)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:11.167363+00:00
License: CC0 · commercial use OK